Pharvaris stock reiterated Buy at H.C. Wainwright on HAE therapy potential
H.C. Wainwright reiterated a Buy rating and $60 price target on Pharvaris (PHVS) due to positive Phase 3 data for deucrictibant, showing an 83% reduction in HAE attacks. The firm sees potential in treating acquired angioedema and expects FDA approval by April 2027. PHVS shares are down 19% since September 2026, trading at $30.49 with a $2.14B market cap. Analysts project significant upside, with price targets ranging from $41 to $79.
How this was made
The 30-second read
Why it matters
Analyst upgrades and a new $60 target suggest the market may re‑price the stock higher, especially given the unmet need in acquired angioedema.
Market read
The trial data and analyst upgrades provide fresh, material information that could move PHVS price in the short term.
What to watch
Potential competition from other HAE therapies and reimbursement uncertainties.
Background
Pharvaris (NASDAQ:PHVS) is developing an oral bradykinin B2 receptor antagonist for hereditary angioedema (HAE). The CHAPTER-3 Phase 3 trial just reported strong efficacy results.
Ticker impact
H.C. Wainwright reiterated a Buy rating with a $60 price target after positive Phase 3 trial data for deucrictibant in hereditary angioedema.
upside pressure as investors price in the trial success and higher price targets.
The trial showed an 83% reduction in attack rates, prompting multiple analysts to raise targets, indicating strong upside potential.
Market effects
Positive data may boost sentiment in the rare‑disease biotech sector.
US biotech investors likely to respond positively.
Limited to pharma/biotech investors.
Counterpoint
If the drug faces regulatory hurdles or commercial uptake is slower than expected, the upside could be limited.
Key entities
- CompanyPharvaris B.V.
Biotech firm developing deucrictibant for HAE.
- AnalystH.C. Wainwright
Reiterated Buy rating with $60 target.
